Literature DB >> 2996920

An analysis of factors predisposing to chronic graft-versus-host disease.

O Ringdén, T Paulin, B Lönnqvist, B Nilsson.   

Abstract

Among 75 consecutive allogeneic bone marrow transplant recipients, 24 developed chronic graft-versus-host disease (GVHD), which was diagnosed from day 31 to day 368 after transplantation. Eight (33%) patients had more extensive chronic GVHD, and five patients died. The actuarial incidence of chronic GVHD was 48% at 400 days. A number of factors were analyzed for their association with chronic GVHD. Recipients of marrow from donors over 17 years of age had an actuarial incidence of chronic GVHD at 400 days of 74%, compared with 27% if the donors were under 17 years of age (log-rank test on survival curves, p less than 0.001). Other factors that appeared to predispose for chronic GVHD in bivariate analysis were recipient age above 17 years (p less than 0.02), treatment with donor unirradiated buffy-coat cells (p less than 0.01), grade-II-IV acute GVHD (p less than 0.01), and a preceding cytomegalovirus (CMV) infection (p less than 0.01). In multi-variate analysis, however, only donor age above 17 years, treatment with donor buffy-coat cells, and grade-II-IV acute GVHD were significantly associated with chronic GVHD. The possible role of CMV infection in the development of chronic GVHD is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996920

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

Review 2.  Graft-versus-host disease of the intestine.

Authors:  G J Cox; G B McDonald
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Authors:  Jose A Pérez-Simón; Gabriel Afram; Rodrigo Martino; Jose L Piñana; Teresa Caballero-Velazquez; Olle Ringden; David Valcarcel; Dolores Caballero; Mats Remberger; Yanira de Paz; Jordi Sierra; Jesús San Miguel; Hans Hagglund
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 4.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

5.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Effie W Petersdorf; J Lee Nelson; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; John A Hansen; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2013-04-01       Impact factor: 22.113

6.  Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.

Authors:  Sally Arai; Madan Jagasia; Barry Storer; Xiaoyu Chai; Joseph Pidala; Corey Cutler; Mukta Arora; Daniel J Weisdorf; Mary E D Flowers; Paul J Martin; Jeanne Palmer; David Jacobsohn; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

7.  Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Sally Arai; Mukta Arora; Tao Wang; Stephen R Spellman; Wensheng He; Daniel R Couriel; Alvaro Urbano-Ispizua; Corey S Cutler; Andrea A Bacigalupo; Minoo Battiwalla; Mary E Flowers; Mark B Juckett; Stephanie J Lee; Alison W Loren; Thomas R Klumpp; Susan E Prockup; Olle T H Ringdén; Bipin N Savani; Gérard Socié; Kirk R Schultz; Thomas Spitzer; Takanori Teshima; Christopher N Bredeson; David A Jacobsohn; Robert J Hayashi; William R Drobyski; Haydar A Frangoul; Görgün Akpek; Vincent T Ho; Victor A Lewis; Robert Peter Gale; John Koreth; Nelson J Chao; Mahmoud D Aljurf; Brenda W Cooper; Mary J Laughlin; Jack W Hsu; Peiman Hematti; Leo F Verdonck; Melhelm M Solh; Maxim Norkin; Vijay Reddy; Rodrigo Martino; Shahinaz Gadalla; Jenna D Goldberg; Philip L McCarthy; José A Pérez-Simón; Nandita Khera; Ian D Lewis; Yoshiko Atsuta; Richard F Olsson; Wael Saber; Edmund K Waller; Didier Blaise; Joseph A Pidala; Paul J Martin; Prakash Satwani; Martin Bornhäuser; Yoshihiro Inamoto; Daniel J Weisdorf; Mary M Horowitz; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-30       Impact factor: 5.742

8.  Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.

Authors:  Yoo-Jin Kim; Dong-Wook Kim; Seok Lee; Chang-Ki Min; Dong-Gun Lee; Soo-Mi Choi; Ki-Seong Eom; Hee-Je Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Steven Z Pavletic; Claudio Anasetti; A John Barrett; Tao Wang; Dan Wang; Joseph H Antin; Paolo Di Bartolomeo; Brian J Bolwell; Christopher Bredeson; Mitchell S Cairo; Robert P Gale; Vikas Gupta; Theresa Hahn; Gregory A Hale; Jorg Halter; Madan Jagasia; Mark R Litzow; Franco Locatelli; David I Marks; Philip L McCarthy; Morton J Cowan; Effie W Petersdorf; James A Russell; Gary J Schiller; Harry Schouten; Stephen Spellman; Leo F Verdonck; John R Wingard; Mary M Horowitz; Mukta Arora
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

Review 10.  Correlation of pretransplant viral serology and complications of bone marrow transplantation.

Authors:  O Ringdén
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.